開拓藥業(09939.HK)普克魯胺治療COVID-19男性患者臨牀試驗獲批
開拓藥業-B(09939.HK)公佈,普克魯胺用於治療輕中症男性新冠(COVID-19)患者的III期臨牀試驗正式獲得巴西國家衛生監督局批準。是繼FDA(美國食品和藥物管理局)同意開展兩項註冊性III期臨牀試驗後,普克魯胺針對COVID-19治療的第三項全球多中心III期臨牀試驗。
臨牀試驗的主要終點爲在第28天前需要氧氣的受試者百分比。預期今年7月進行首例患者給藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.